Facebook
Twitter
Telegram
Report an ErrorObalon Therapeutics, Inc. Financial Ratios 2011-2024 | OBLN
Annual Financial Ratios Obalon Therapeutics, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-2.8 | -0.4 | -0.9 | -2.1 | -2.1 | - | - | - | - | - |
P/S |
22.0 | 2.6 | 3.6 | 7.4 | 12.5 | - | - | - | - | - |
EV/EBITDA |
-4.2 | 0.3 | -0.6 | -1.8 | 1.1 | - | - | - | - | - |
PEG |
-0.04 | -0.0 | -0.15 | -0.04 | 0.01 | - | - | - | - | - |
P/B |
7.5 | 0.5 | 2.5 | 2.1 | 0.7 | - | - | - | - | - |
P/CF |
-3.3 | -0.4 | -1.1 | -2.3 | -2.2 | - | - | - | - | - |
ROE % |
-264.39 | -149.38 | -285.19 | -99.01 | -31.83 | - | - | - | - | - |
ROA % |
-116.17 | -116.10 | -123.02 | -65.47 | -25.98 | - | - | - | - | - |
ROCE % |
-191.02 | -141.51 | -281.00 | -79.81 | -26.29 | - | - | - | - | - |
DSO |
724.0 | 31.7 | 35.4 | 158.6 | 55.9 | - | - | - | - | - |
DIO |
- | 239.5 | 106.3 | 107.2 | 107.5 | - | - | - | - | - |
DPO |
223.6 | 80.2 | 78.0 | 96.4 | 77.3 | - | - | - | - | - |
All numbers in USD currency